Alkermes Q2 2023 revenues $617.4M, GAAP net income $237.1M on arbitration win

Alkermes plc.

2023-Q2 EPS reported $1.14 revenue$904,992,000

Total revenues $617.4M including $248.4M back royalties from Janssen arbitration; proprietary product sales up 21% YoY to $231.5M.
GAAP net income $237.1M ($1.43 basic EPS) vs net loss $30.1M in Q2 2022; non-GAAP net income $94.3M ($0.57 EPS).
LYBALVI net sales $47.0M (+134% YoY); VIVITROL $102.1M (+6%); ARISTADA $82.4M (+10%).
Cash and investments $907.2M; FY 2023 financial expectations reiterated, including accretive INVEGA royalties.
Oncology separation into Mural Oncology on track for H2 2023; Caroline Loew appointed CEO designate.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alkermes plc. updated its three and six months ended June 30, 2023 guidance (reaffirmed).

Period: three and six months ended June 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On July 26, 2023, Alkermes plc (the “Company”) announced financial results for the three and six months ended June 30, 2023.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Alkermes plc. filing history →

Source: SEC EDGAR

accession 0000950170-23-034556

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.